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1. Introduction
1.1. Excision margins for primary tumor
Although surgical excision of the primary melanoma is internationally accepted as the treat‐
ment of choice, several questions concerning the follow-up schedule are still debated contro‐
versially. Incision biopsies should be avoided, except in selected cases (wide lesions or
critical anatomic locations). Excision biopsy is preferred to give the dermatopathologist an
optimal specimen and to allow evaluation of the excision margins for residual tumor. Since
the beginning of the last century, the recommendation has been to excise a primary melano‐
ma with safety margins. In 1907 Handley [1] analyzed the pattern of satellite metastases in
melanoma and recommended excision of the primary tumor with a margin of 1 inch (2.54
cm) from the edge of the tumor. In the 1970s and 1980s, safety margins of 5 cm, independent
of tumor thickness, were the surgical standard.[2] The World Health Organization Melano‐
ma Group performed the first surgical trial to compare lower safety margins of 1 and 3 cm
in primary melanomas with less than 2 mm of tumor thickness.[3] The group found no dif‐
ferences in survival and only slightly increased local recurrence rates in the patients with
narrower excision margins. These results led to the recommendation of 1-cm margins in pa‐
tients with primary melanomas with less than 1 mm tumor thickness. Later comparisons of
5- and 2-cm safety margins in thick primary melanomas revealed no significant advantages
for the 5-cm margins.[4] A recent trial, however, comparing 1- and 3-cm safety margins in
thick primary melanoma with 2 mm and more tumor thickness showed an increased rate of
local recurrence in those with the small safety margins and a simultaneous trend towards
decreased survival rates. These findings indicate that the safety margin cannot be reduced to
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zero in melanoma.[5] Different national guidelines now give uniform recommendations for
the excision of primary melanoma.[6-9]
2. Sentinel lymph node biopsy and lymph node dissection
Metastasis to regional nodes is the most important prognostic factor in patients with early-
stage melanoma and has been shown to occur in approximately 20% of patients with inter‐
mediate-thickness tumors.[10,11] As such, it is critically important to identify those patients
for whom the expected benefits of resecting regional lymph nodes outweigh the risks of sur‐
gical morbidity. The technique of lymphatic mapping and sentinel lymph node (SLN) biop‐
sy for melanoma has emerged during the last 2 decades as a minimally invasive approach to
evaluate regional lymph node basins in patients with intermediate- and high-risk primary
cutaneous melanoma. Goals of SLN biopsy include accurate nodal staging, identification of
patients with clinically occult, microscopic lymph node disease who may benefit from fur‐
ther treatment, regional nodal control, and a possible survival benefit.[12,13] Moreover, this
approach may also identify a subset of patients for whom further treatment is not indicated,
sparing them from unnecessary surgical procedures or systemic therapies.[12,13] In this re‐
view, we examine the evolution of SLN biopsy as a technique, the preoperative assessment
and operative strategy, the pathologic evaluation of the SLN, the current practice guidelines,
the prognostic significance of SLN biopsy findings, and the potential complications of the
procedure and address some of the current areas of controversies in the field. Sentinel
lymph node (SLN) biopsy is commonly used in melanoma and has been endorsed by the
American Joint Committee on Cancer (AJCC) as a valuable staging procedure for patients
with melanoma who are at risk of clinically occult nodal metastases. This highly accurate
and low-morbidity staging procedure should be used to guide treatment decisions (ie, com‐
pletion lymph node dissection [CLND] and adjuvant therapy) as well as entry into clinical
trials.[14] To develop and formalize guideline recommendations for the use of SLN biopsy
in oncology practice, the American Society of Clinical Oncology (ASCO) and Society of Sur‐
gical Oncology (SSO) convened a joint Expert Panel in order to better define what are the
indications for SLN biopsy as well as what is the role of CLND. SLN biopsy is recommend‐
ed for patients with intermediate-thickness cutaneous melanomas (Breslow thickness, 1 to 4
mm) of any anatomic site. Routine use of SLN biopsy in this population provides accurate
staging. Although there are few studies focusing specifically on patients with thick melano‐
mas (T4; Breslow thickness, > 4 mm), use of SLN biopsy in this population may be recom‐
mended for staging purposes and to facilitate regional disease control. There is insufficient
evidence to support routine SLN biopsy for patients with thin melanomas (T1; Breslow
thickness, < 1 mm), although it may be considered in selected patients with high-risk fea‐
tures when the benefits of pathologic staging may outweigh the potential risks of the proce‐
dure. Such risk factors may include ulceration or mitotic rate ≥ 1/mm2, especially in the
subgroup of patients with melanomas 0.75 to 0.99 mm in Breslow thickness. After a positive
SLN biopsy, 97.5% of patients underwent CLND, and 20.1% were found to have additional
positive lymph nodes. Overall, the recurrence rate in the same nodal basin after a positive
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SLN biopsy was 7.5%, despite CLND in nearly all patients.[15] Overall, the SLN biopsy pro‐
cedure is well tolerated and associated with low complication rates.[16] Although clinical
variables such as older age have been variably reported as lower risk factors,[17-19] there
are no specific variables that can reliably identify patients with intermediate-thickness mela‐
nomas at low risk for metastases. The definition of intermediate-thickness melanoma varied
by study. Nevertheless, it is clinically consistent with contemporary staging systems to de‐
fine intermediate-thickness melanomas as those measuring 1 to 4 mm.[20] Clinical judgment
must be used when considering SLN biopsy in patients with comorbid medical conditions.
The individual risks and benefits of the procedure should be weighed against the operative
and anesthetic risks as well as potential competing causes of mortality. Complications after
SLN biopsy are uncommon. The overall complication rate reported in the Multicenter Selec‐
tive Lymphadenectomy Trial I (MSLT I) was 10.1% after SLN biopsy compared with 32.7%
after CLND.[21] The most common complications after SLN removal documented in MSLT I
included seroma (5.5%), infection (4.6%), and wound separation (1.2%). The Sunbelt Mela‐
noma Trial similarly showed a low overall rate of complications from SLN biopsy (4.6%)
compared with CLND (23.2%).[16,17] Most complications were noted to be short-term is‐
sues that resolved over time with wound care and selective use of antibiotics. Accurate iden‐
tification of patients with node-negative (stage I or II) or node-positive (stage III) disease
improves staging and may facilitate regional disease control and decision making for treat‐
ment with adjuvant therapy.[14,22] With substantive changes in the melanoma staging
guidelines in 2002, the AJCC staging system effectively linked disease stage and prognosis.
[23,24] At that time, the number of nodal metastases and whether nodal disease was occult
or clinically apparent (ie, how the N category was defined with regard to burden of disease)
were noted to be the most significant independent predictors of survival in patients with
stage III melanomas. With later iterations of the last AJCC staging system,[10] additional re‐
finements were made in the N category based on the prognostic value of distinguishing mi‐
crometastases (as would be diagnosed after SLN biopsy) from macrometastases.[25,26] A
melanoma macrometastasis is detected by clinical examination (not by size criteria) and con‐
firmed pathologically, whereas a melanoma micrometastasis is a clinically occult nodal
metastasis that is detected by a pathologist on microscopic examination of lymph nodes,
with or without immunohistochemistry, and is not limited by any minimum or maximum
size threshold. Recognizing the value of examining SLNs to detect low volumes of metastat‐
ic disease (aggregates of only a few cells), the current staging system[10,27] incorporates the
use of immunohistochemistry and eliminates any minimum size threshold for defining no‐
dal metastases. Molecular diagnostics, such as reverse transcriptase-polymerase chain reac‐
tion, have unproven prognostic significance, and these results are not used to define positive
nodes. As a result, more refined definitions of the N category are now used for classification.
Distinct differences in classifications have validated prognostic significance. For example, 5-
year survival ranges from 70% for patients with one SLN positive with micrometastatic dis‐
ease to 39% for patients with > four involved nodes or with nodes that are extensively
involved (eg, matted nodes).1 Although SLN biopsy has been widely accepted for the patho‐
logic staging of patients with intermediate-thickness melanomas, somewhat more contro‐
versy exists regarding the value of this procedure for patients with thick primary tumors
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(T4; Breslow thickness, > 4 mm). Conventional wisdom asserts that patients with thick mela‐
nomas have a high risk of systemic disease at the time of diagnosis and that no survival ben‐
efit can be derived from removal of regional lymph nodes. However, among patients
without distant disease, it can be argued that those with thick melanomas have indications
for SLN biopsy similar to those of patients with intermediate-thickness melanomas and de‐
rive the same benefits from SLN biopsy as a pathologic staging procedure. One of the main
advantages of SLN biopsy in patients with thick melanomas is better regional disease con‐
trol, which is especially important in a population with > 30% chance of lymph node in‐
volvement.[25,28] Evidence from multiple retrospective studies has demonstrated that SLN
biopsy provides important staging and prognostic information for patients with thick mela‐
nomas. Seven of eight published studies-each evaluating SLN biopsy in > 100 patients with
T4 melanomas-have shown that SLN biopsy is a significant predictor of overall survival.
[11,25,26,28-33] The one study that did not show a significant difference in overall survival
demonstrated a significant difference in disease-free survival.[29] A majority (70%) of mela‐
nomas diagnosed are thin melanomas (T1; Breslow thickness, < 1 mm).[34] In general, the
routine use of SLN biopsy in patients with thin melanomas has not been advocated, because
the overall risk of nodal involvement is estimated to be only approximately 5.1%,[35] al‐
though there are reports of positive SLNs in up to 20% of patients in subsets with thin mela‐
nomas (especially those that are 0.75 to 0.99 mm in thickness with ulceration and/or mitotic
rate ≥ 1/mm2).[27] An individualized approach to SLN biopsy for patients with thin melano‐
mas has been advocated in many treatment centers based on risk factors that have been
shown to be associated with SLN metastasis. Further investigation is also needed to better
identify the subgroups of patients with thin melanomas with a greater risk of nodal metasta‐
sis. CLND is recommended for all patients with a positive SLN biopsy. CLND achieves re‐
gional disease control, although whether CLND after a positive SLN biopsy improves
survival is the subject of the ongoing Multicenter Selective Lymphadenectomy Trial II
(MSLT II). Currently, CLND is the standard recommendation for patients with tumor-posi‐
tive SLNs. The goals of CLND are to improve survival rates, maximize regional disease con‐
trol, and minimize operative morbidity. Whether CLND improves survival is the subject of
the ongoing prospective randomized MSLT II study.[36] The main objective of MSLT II is to
determine if there is a therapeutic benefit to removing any non-SLNs in patients who have
already had their tumor-positive SLN removed. In MSLT I, patients with demonstrated no‐
dal metastases had a survival advantage with early intervention compared with those who
had a delayed lymphadenectomy when they presented with clinically evident nodal meta‐
stases.[5] Hence, although two goals of CLND are regional disease control and cure, there is
currently insufficient evidence to determine whether omission of CLND is safe. In the two
large prospective randomized trials (ie, the Sunbelt Melanoma Trial and MSLT I), the rate of
positive non-SLNs among patients who underwent CLND for a tumor-positive SLN was
16%.[17,37] In a retrospective multi-institutional study by Wong et al,[38] which included
134 highly selected patients with positive SLNs who did not undergo CLND, regional nodal
metastasis was a component of first recurrence in 15% of these patients. Therefore, it is rea‐
sonable to conclude from these data that the risk of developing regional nodal metastasis as
a first site of recurrence, if no CLND is performed, is at least 15% to 20%.[39,40] In MSLT I,
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the rate of regional nodal recurrence after CLND was 4.2%5; in the Sunbelt Melanoma Trial,
it was 4.9% (unpublished data). These rates are much lower than the 15% rate of regional
nodal recurrence as a site of first metastasis and the 41% overall regional nodal recurrence
rate when CLND was not performed, reported in the study by Wong et al.[37] Until final
results of MSLT II are available, we will not be able to determine, with higher-level evi‐
dence, the impact of CLND on regional disease control. Until that time, the best available
evidence suggests that CLND is effective at achieving regional disease control in the majori‐
ty of patients with positive SLNs. MSLT I showed no benefit of CLND with regard to overall
survival, likely because only a minority of patients (16%) had tumor-positive SLNs, and the
majority of the patients in the study would not have been helped by removal of regional
lymph nodes.[37] However, the 5-year survival rate for patients with tumor-positive SLNs
who underwent CLND was 72.3% compared with 52.4% for patients who did not undergo
SLN biopsy and developed palpable nodal disease (hazard ratio, 0.51; 95% CI, 0.32 to 0.81; P
=.004). CLND should be performed until there is convincing evidence that it does not im‐
prove regional disease control or survival. CLND is associated with risks of long-term mor‐
bidity, especially lymphedema. However, morbidity with CLND may be considerably
worse when it is delayed until there is clinically evident disease. The observed increases in
morbidity for patients who have undergone therapeutic lymphadenectomy for palpable dis‐
ease and the increased morbidity associated with radiation therapy support the continued
use of CLND for patients with a positive SLN biopsy rather than delayed CLND for palpa‐
ble disease. There is a need for future clinical trials to address many unresolved research
questions related to the use of SLN biopsy in patients with melanoma. These include: deter‐
mining precise criteria for selecting which patients should undergo SLN biopsy, determin‐
ing whether early identification of metastases in the SLN truly improves survival or merely
represents lead-time bias, identifying which criteria for individualized risks best inform ap‐
propriate risk stratification for patients at high risk for relapse and those for whom CLND
and/or adjuvant therapy are suitable, and establishing the role of prognostic markers from
the primary melanoma and SLN to help assign appropriate risk stratification. Results from
MSLT II, in which patients were randomly assigned to CLND or observation, will help de‐
termine whether there is any benefit to CLND after a positive sentinel node in patients with
melanoma. Answers to these questions will assist clinicians and patients with making deci‐
sions and ultimately help to identify patients who may avoid expensive and intrusive proce‐
dures in staging and follow-up.
3. Treatment of in transit metastases
In 5–8% of cases, melanoma patients will develop in-transit metastasis (IT-mets). Standard
regional treatment options include surgical resection, isolated limb perfusion (ILP), isolated
limb infusion (ILI) and Electrochemotherapy. As regional recurrence often precedes system‐
ic disease, amputative surgery is in general no longer practiced, although old series of radi‐
cal surgery have demonstrated that some patients with IT-mets confined to the limb can be
cured.[42,43] Simple surgical resection may suffice for incidental and low numbers of IT-
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mets. In cases of rapid recurrences and multiple IT-mets, other techniques must provide an
attractive treatment option that can improve local control markedly and thereby quality of
life. ILP, developed by Creech et al., achieves a 20-fold higher concentration of chemothera‐
peutic drugs when compared with systemic therapy.[44,45] Melphalan-based ILP (M-ILP)
has been the standard treatment and has been reported to achieve overall complete response
(CR) rates in the range of about 50%.[46]In general large IT-mets showed a poor response
and inhomogeneous uptake comparable with locally advanced soft tissue sarcomas (STS).
The introduction of tumor necrosis factor-α (TNF) changed this situation dramatically.
Large tumors now reacted very well to ILP.[47] This led to a successful multicenter trial in
Europe and the approval of TNF-based ILP (TM-ILP) for unresectable extremity soft tissue
sarcomas (STS).[48] Similar encouraging results were reported for the use of TNF in ILP for
melanoma patients.[49] Preclinical and clinical studies suggested that a reduction of the
dose of TNF to 1 mg for the arm and 2 mg for the leg might be as effective as the higher
doses.[50-53]Isolated limb infusion (ILI) is a minimally invasive technique for delivering
high-dose regional chemotherapy in locally advanced melanoma. It was first described by
Thompson et al. in 1994 from the Sydney Melanoma Unit as a simplified alternative to ILP
[54,55]. Percutaneous arterial and venous catheters are placed in the affected extremity by
interventional radiologists and a tourniquet is placed proximal to the catheter tips to allow
isolation of the limb from the systemic circulation. High-dose chemotherapy (e.g. melphalan
and actinomycin-D) is infused into a hyperthermic, hypoxic limb via the arterial catheter
and blood is withdrawn from the venous catheter to be re-infused into the arterial side.
Therefore, it is a quicker, safer, and cheaper procedure with reported response rates compa‐
rable to ILP.[56,57] Although the primary indication for this technique is melanoma, it has
been successfully applied to other tumors such as soft-tissue sarcomas,[58] Merkel cell tu‐
mor,[59] and cutaneous T-cell lymphoma.[60]
Electrochemotherapy (ECT) represents an effective therapeutic option for skin tumors that
has received experimental and clinical support in recent years.[61-71] The European stand‐
ard operating procedures for ECT emphasize the technical aspects of the procedure and
have established this treatment in clinical practice.[72,73] In recent years, the effectiveness of
ECT treatment has been confirmed in several small series of patients with melanoma.[71] At
present, ECT is employed routinely with encouraging results not only for superficial tumor
control but also to preserve quality of life.[70]Patients with regional or distant skin or subcu‐
taneous metastases, with or without visceral disease, could undergo this technique. Eligibili‐
ty criteria were the following: melanoma stage IIIC–IV (American Joint Committee on
Cancer, 6th edition)[74] lesions no deeper than 3 cm suitable for electrode insertion; no anti‐
cancer treatments 4 weeks before and 8 weeks after ECT; age more than 18 years; and an
Eastern Cooperative Oncology Group performance status equal to or less than 2. Exclusion
criteria included: allergy to Bleomycin; pulmonary, cardiac or liver impairment; epilepsy;
life expectancy less than 3 months; active infection; brain metastases; and cardiac pacemaker
in patients with chest wall metastases. Bleomycin is administered intravenously (15 000
units/m2 in a bolus administered over 60 s) and was followed, within 8 min after intrave‐
nous injection, by the application of brief electric pulses to each tumor nodule. Electric cur‐
rents were delivered by means of a 2–3-cm long needle electrode according to lesion size.
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The electrodes were connected to a pulse generator (Cliniporator™; Igea, Modena, Italy).
This generator produces high voltages (up to 1000 V), but delivered as a compressed train of
eight pulses at a frequency of 5000 Hz and 100 µs duration, and therefore well tolerated by
the patient. The software controls and stores the applied voltage and the actual current de‐
livered to each tumor. ECT could be repeated every 8–12 weeks according to local response,
the appearance of new lesions and the patient's tolerance of the treatment.
4. Surgical approach for distant metastases
Conventional teaching maintains that resection is not indicated in patients with distant
metastases, except for palliation. This dogma stems from the concept that patients with mul‐
tiple metastases usually also have occult micrometastases and circulating tumor cells. How‐
ever the results of surgical treatment of stage IV melanoma patients have improved
considerably over the past two decades. Recent studies [75] provide further evidence of the
beneficial role of surgery for distant metastases of melanoma. Our findings indicate a sur‐
vival advantage for a surgical approach, even in patients with high-risk visceral metastases
or multiple metastases that may require multiple operations for complete resection. At least
55 % of stage IV patients may be eligible to undergo surgery as part of their treatment plan
and the surgeon should play an integral role in evaluation and treatment planning for all
patients with stage IV recurrence of melanoma. One potential therapeutic advantage of re‐
section is that it may delay disease progression by interrupting the metastatic cascade asso‐
ciated with hematogenous seeding of cells to other sites.[76]In addition, it immediately
reduces tumor burden and thereby decreases tumor-induced immune suppression.[77] Fi‐
nally, metastasectomy may enhance the patient’s endogenous immune defences or response
to adjuvant immunotherapy and thus maintain a complete clinical remission. Surgery for
distant metastases has been improved by development of more advanced imaging techni‐
ques that can detect lesions as small as 5–10 mm.[78] These techniques can differentiate pa‐
tients with multiple versus limited metastases, allowing surgeons to better judge the extent
of disease and plan the operative procedure necessary for complete resection. In addition,
modern advances in anaesthesia, surgical techniques and supportive care have reduced op‐
erative mortality from multiple metastasectomy with a corresponding reduction in morbidi‐
ty and finally, shorter postsurgical hospitalizations have decreased the total costs of cancer
surgery. Surgical therapy for stage IV disease remains controversial. The development of
metastases is a complex process and the rationale for surgical resection of metastatic mela‐
noma is multifactorial. First, reduction of tumor burden through surgical resection limits
disease progression by interrupting the metastatic cascade associated with haematogenous
seeding of cells to other sites. Unlike chemotherapy, surgery can easily eradicate tumor
masses 2 cm or larger. Second, surgery may reverse tumor-induced immunosuppression, re‐
storing immune function and inhibiting metastatic progression. Third, most patients tolerate
surgical resection to a much greater extent than they can tolerate adverse effects of systemic
therapy and recurrences after initial metastasectomy can also be treated through a secon‐
dary resection of metastases. Last, metastasectomy does not preclude systemic therapy;
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however, if metastasectomy is delayed, increasing tumor burden may make disease unre‐
sectable. In addition the advent of newer and better systemic therapies makes the role of
surgical resection more relevant today than ever before. Timing of surgery versus systemic
treatment is another important end point. The development of new and effective drugs in
the systemic treatment of stage IV melanoma patients have been reported recently, with the
BRAF inhibitor Vemurafinib and the monoclonal antibody Ipilimumab; other targeted drugs
are being developed, and some are currently being tested in the clinical setting. Thus a ther‐
apeutic strategy combining new drugs with aggressive surgery in selected cases of melano‐
ma metastatic disease could be designed in the following years.
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